US2013184258A1PendingUtilityA1
Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels
Est. expiryAug 8, 2023(expired)· nominal 20-yr term from priority
A61P 31/22A61P 43/00A61P 9/06A61P 3/10A61P 25/00A61P 25/04A61P 25/22A61P 25/28A61P 25/02A61P 25/14A61P 25/06A61P 29/00A61P 25/24A61P 25/08A61P 25/18A61P 25/12A61P 25/10A61P 1/00A61P 1/02A61P 1/04A61P 13/02A61P 19/02C07D 213/76C07D 239/545C07D 237/22C07D 513/04C07C 2601/08C07D 285/135C07D 239/69C07D 239/52C07C 311/46C07C 311/51C07D 409/12C07D 231/38C07D 417/14C07D 405/14C07D 231/42C07D 417/12C07C 2601/14C07D 295/26C07D 403/12C07D 401/12C07D 263/50C07D 413/12C07D 261/16C07D 239/47C04B 35/632C07D 241/22C07D 405/12C07D 237/20C07D 277/52C07D 209/80C07D 407/12C07D 209/92C07D 285/125C07D 277/82C07D 239/42C07C 2601/02
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Claims
exact text as granted — not AI-modified1 . A compound selected from the following table:
#
Compound
3
4
6
7
9
16
17
18
22
23
24
26
27
28
29
33
36
38
43
47
50
51
55
58
61
66
67
68
71
74
75
81
88
89
90
91
92
93
94
95
96
103
104
109
110
112
117
118
121
123
124
127
129
131
132
134
135
137
138
139
140
141
143
148
149
151
158
161
162
163
164
165
166
167
168
170
171
172
173
174
175
177
182
186
250
258
273
278
279
294
302
303
312
313
314
315
316
317
339
342
345
350
353
356
357
360
361
364
365
368
370
373
375
376
380
383
388
391
393
395
398
399
400
403
406
409
410
411
412
413
414
415
416
417
418
419
420
421
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
488
489
490
491
492
495
497
498
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
539
542
543
544
545
546
547
548
549
551
552
553
554
555
556
558
559
560
561
565
566
567
569
570
571
572
573
578
580
584
586
587
590
591
593
594
595
596
598
599
600
601
602
603
604
606
608
609
610
613
614
623
624
625
626
627
645
646
697
698
699
701
702
703
717
718
719
720
728
729
730
731
732
733
734
735
736
737
738
739
748
749
750
751
752
753
754
755
756
757
758
759
760
771
772
773
or a pharmaceutically acceptable salt thereof.
2 - 75 . (canceled)
76 . A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable adjuvant or carrier.
77 - 116 . (canceled)Join the waitlist — get patent alerts
Track US2013184258A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.